Abstract:BACKGROUND:Radiotherapy does not show good efficacy against laryngeal cancer due to radioresistance. Cancer stem cells (CSCs) are considered among the causes of radioresistance. Inhibition of glucose transporter-1 (GLUT-1) using GLUT-1 small interfering RNA (siRNA) may enhance the radiosensitivity of laryngeal cancer cells, but the underlying cellular mechanisms remain unclear.METHODS:The CD133+-Hep-2R cell line was established with repeated irradiation and magnetic-activated cell sorting. The effects of irradiation on CD133+-Hep-2R cells were examined by CCK-8 assay, Transwell assay, quantitative real-time polymerase chain reaction (RT-PCR), and Western blotting. The effects of GLUT-1 siRNA on the radiosensitivity of CD133+-Hep-2/2R cells were examined by RT-PCR, Western blotting, CCK-8 assay, colony formation assay, and Transwell assay in vitro and in a xenograft tumor model in nude mice. The cellular mechanism of enhanced radiosensitivity associated with GLUT-1 siRNA was investigated. The cell cycle and apoptosis rate were analyzed by flow cytometry, and the repair capability was examined by determining the levels of RAD51 and DNA-PKcs.RESULTS:CD133+-Hep-2/2R cells showed stronger proliferation, lower apoptosis rate, lower percentage of G0/G1 phase cells, higher percentages of S and G2/M phase cells, and higher expression levels of GLUT-1 than Hep-2/2R cells. Transfection with GLUT-1 siRNA inhibited the proliferation and invasive capability of CD133+-Hep-2R cells by inhibiting GLUT-1 expression, which also caused a redistribution of the cell cycle (higher proportion of cells in the G0/G1 phase and lower proportion in the S and G2/M phases), increased the apoptosis rate, and reduced DNA repair capability by suppressing RAD51 and DNA-PKcs expression.CONCLUSION:The results of this study suggest that GLUT-1 siRNA can enhance the radiosensitivity of CD133+-Hep-2R cells by inducing a redistribution of cell cycle phases, inhibiting DNA repair capability, and increasing apoptosis. Inhibition of GLUT-1 may have therapeutic potential for interventions to increase the radiosensitivity of laryngeal CSCs.

Roles of Glucose Transporter-1 and the Phosphatidylinositol 3-Kinase/protein Kinase B Pathway in Cancer Radioresistance (Review)

Effect Of Antisense Oligodeoxynucleotides Glucose Transporter-1 On Enhancement Of Radiosensitivity Of Laryngeal Carcinoma

Roles of GLUT-1 and HK-II Expression in the Biological Behavior of Head and Neck Cancer

GLUT-1 Sirna Enhances Radiosensitization of Laryngeal Cancer Stem Cells Via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis in Vitro and in Vivo.

Co-Inhibition Of Glut-1 Expression And The Pi3k/Akt Signaling Pathway To Enhance The Radiosensitivity Of Laryngeal Carcinoma Xenografts In Vivo

Role of GLUT-1 in the Upregulation of PD-L1 Expression after Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer

Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy

Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics

Emerging Role of High Glucose Levels in Cancer Progression and Therapy

Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression

Targeting Glucose Metabolism of Cancer Cells with Dichloroacetate to Radiosensitize High-Grade Gliomas

Abstract 2872: GLUT3 promotes metabolic plasticity that drives radiation resistance in glioblastoma

Glucose transporters in cancer – from tumor cells to the tumor microenvironment

Novel insight into metabolic reprogrammming in cancer radioresistance: A promising therapeutic target in radiotherapy

The glucose transporter GLUT12, a new actor in obesity and cancer

Altered glycolysis results in drug-resistant in clinical tumor therapy.

Oncogenic Activation of the PI3K/Akt Pathway Promotes Cellular Glucose Uptake by Downregulating the Expression of Thioredoxin-Interacting Protein.

Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy

The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism

Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo

Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC